TLR2 and acute myeloid leukemia: These results suggest that TLR2 and TLR4 could serve as prognostic biomarkers and potential therapeutic targets in AML, as their elevated expressions are associated with adverse clinical outcomes and more aggressive disease characteristics [45], data presented in Table 1.